(CLB) Core Laboratories - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: NL0000200384
Reservoir Description, Production Enhancement
Dividends
| Dividend Yield | 0.24% |
| Yield on Cost 5y | 0.16% |
| Yield CAGR 5y | -38.52% |
| Payout Consistency | 84.6% |
| Payout Ratio | 5.2% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 45.9% |
| Value at Risk 5%th | 70.2% |
| Relative Tail Risk | -6.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.04 |
| Alpha | -39.54 |
| CAGR/Max DD | -0.03 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.445 |
| Beta | 1.546 |
| Beta Downside | 1.581 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.29% |
| Mean DD | 31.77% |
| Median DD | 33.02% |
Description: CLB Core Laboratories October 23, 2025
Core Laboratories Inc. (NYSE: CLB) delivers reservoir description and production-enhancement services to oil- and-gas operators worldwide, operating through two segments: Reservoir Description, which characterizes rock and fluid samples to boost recovery, and Production Enhancement, which supplies well-completion, stimulation, and diagnostic solutions for improved well performance and EOR projects.
Key performance indicators from recent filings show FY 2023 revenue of roughly $1.1 billion with an operating margin near 14 %, while the company’s cash flow remains sensitive to upstream capital-expenditure cycles and oil-price volatility-core economic drivers that can swing demand for its laboratory and field services.
Sector-wide, CLB benefits from rising upstream spending on enhanced-oil-recovery techniques and carbon-capture initiatives, both of which are accelerating as regulators tighten emissions standards and producers seek to extend field life; however, a prolonged downturn in drilling activity could compress service pricing and utilization rates.
For a deeper quantitative view of CLB’s valuation relative to peers, the ValueRay platform offers a concise, data-driven dashboard worth checking.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (32.1m TTM) > 0 and > 6% of Revenue (6% = 31.1m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -1.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 25.35% (prev 26.83%; Δ -1.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 50.5m > Net Income 32.1m (YES >=105%, WARN >=100%) |
| Net Debt (141.5m) to EBITDA (73.1m) ratio: 1.94 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (47.1m) change vs 12m ago -1.55% (target <= -2.0% for YES) |
| Gross Margin 17.12% (prev 18.30%; Δ -1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 86.84% (prev 87.07%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.17 (EBITDA TTM 73.1m / Interest Expense TTM 10.6m) >= 6 (WARN >= 3) |
Altman Z'' 3.59
| (A) 0.22 = (Total Current Assets 226.9m - Total Current Liabilities 95.7m) / Total Assets 591.4m |
| (B) 0.29 = Retained Earnings (Balance) 173.6m / Total Assets 591.4m |
| (C) 0.09 = EBIT TTM 54.7m / Avg Total Assets 595.9m |
| (D) 0.54 = Book Value of Equity 168.1m / Total Liabilities 314.0m |
| Total Rating: 3.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.48
| 1. Piotroski 5.0pt |
| 2. FCF Yield 4.04% |
| 3. FCF Margin 6.74% |
| 4. Debt/Equity 0.62 |
| 5. Debt/Ebitda 1.94 |
| 6. ROIC - WACC (= 1.65)% |
| 7. RoE 12.38% |
| 8. Rev. Trend 66.86% |
| 9. EPS Trend 44.47% |
What is the price of CLB shares?
As of December 08, 2025, the stock is trading at USD 16.83 with a total of 486,246 shares traded.
Over the past week, the price has changed by +11.46%, over one month by +7.20%, over three months by +33.44% and over the past year by -15.00%.
Over the past week, the price has changed by +11.46%, over one month by +7.20%, over three months by +33.44% and over the past year by -15.00%.
Is CLB a buy, sell or hold?
Core Laboratories has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold CLB.
- Strong Buy: 0
- Buy: 1
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CLB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14 | -16.8% |
| Analysts Target Price | 14 | -16.8% |
| ValueRay Target Price | 18.1 | 7.5% |
CLB Fundamental Data Overview December 03, 2025
Market Cap USD = 721.7m (721.7m USD * 1.0 USD.USD)
P/E Trailing = 22.6324
P/E Forward = 19.7628
P/S = 1.3946
P/B = 2.5912
P/EG = 1.6717
Beta = 1.082
Revenue TTM = 517.5m USD
EBIT TTM = 54.7m USD
EBITDA TTM = 73.1m USD
Long Term Debt = 114.1m USD (from longTermDebt, last quarter)
Short Term Debt = 11.5m USD (from shortTermDebt, last quarter)
Debt = 167.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 141.5m USD (from netDebt column, last quarter)
Enterprise Value = 863.2m USD (721.7m + Debt 167.1m - CCE 25.6m)
Interest Coverage Ratio = 5.17 (Ebit TTM 54.7m / Interest Expense TTM 10.6m)
FCF Yield = 4.04% (FCF TTM 34.9m / Enterprise Value 863.2m)
FCF Margin = 6.74% (FCF TTM 34.9m / Revenue TTM 517.5m)
Net Margin = 6.21% (Net Income TTM 32.1m / Revenue TTM 517.5m)
Gross Margin = 17.12% ((Revenue TTM 517.5m - Cost of Revenue TTM 428.9m) / Revenue TTM)
Gross Margin QoQ = 19.35% (prev 17.51%)
Tobins Q-Ratio = 1.46 (Enterprise Value 863.2m / Total Assets 591.4m)
Interest Expense / Debt = 1.59% (Interest Expense 2.65m / Debt 167.1m)
Taxrate = 20.54% (3.75m / 18.3m)
NOPAT = 43.5m (EBIT 54.7m * (1 - 20.54%))
Current Ratio = 2.37 (Total Current Assets 226.9m / Total Current Liabilities 95.7m)
Debt / Equity = 0.62 (Debt 167.1m / totalStockholderEquity, last quarter 271.3m)
Debt / EBITDA = 1.94 (Net Debt 141.5m / EBITDA 73.1m)
Debt / FCF = 4.06 (Net Debt 141.5m / FCF TTM 34.9m)
Total Stockholder Equity = 259.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.43% (Net Income 32.1m / Total Assets 591.4m)
RoE = 12.38% (Net Income TTM 32.1m / Total Stockholder Equity 259.5m)
RoCE = 14.65% (EBIT 54.7m / Capital Employed (Equity 259.5m + L.T.Debt 114.1m))
RoIC = 11.39% (NOPAT 43.5m / Invested Capital 381.8m)
WACC = 9.75% (E(721.7m)/V(888.8m) * Re(11.71%) + D(167.1m)/V(888.8m) * Rd(1.59%) * (1-Tc(0.21)))
Discount Rate = 11.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.50%
[DCF Debug] Terminal Value 70.45% ; FCFE base≈38.5m ; Y1≈47.5m ; Y5≈81.1m
Fair Price DCF = 16.80 (DCF Value 782.1m / Shares Outstanding 46.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 44.47 | EPS CAGR: 2.57% | SUE: 1.90 | # QB: 1
Revenue Correlation: 66.86 | Revenue CAGR: 1.95% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.75 | Chg30d=-0.083 | Revisions Net=-2 | Growth EPS=+1.6% | Growth Revenue=-0.8%
P/E Trailing = 22.6324
P/E Forward = 19.7628
P/S = 1.3946
P/B = 2.5912
P/EG = 1.6717
Beta = 1.082
Revenue TTM = 517.5m USD
EBIT TTM = 54.7m USD
EBITDA TTM = 73.1m USD
Long Term Debt = 114.1m USD (from longTermDebt, last quarter)
Short Term Debt = 11.5m USD (from shortTermDebt, last quarter)
Debt = 167.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 141.5m USD (from netDebt column, last quarter)
Enterprise Value = 863.2m USD (721.7m + Debt 167.1m - CCE 25.6m)
Interest Coverage Ratio = 5.17 (Ebit TTM 54.7m / Interest Expense TTM 10.6m)
FCF Yield = 4.04% (FCF TTM 34.9m / Enterprise Value 863.2m)
FCF Margin = 6.74% (FCF TTM 34.9m / Revenue TTM 517.5m)
Net Margin = 6.21% (Net Income TTM 32.1m / Revenue TTM 517.5m)
Gross Margin = 17.12% ((Revenue TTM 517.5m - Cost of Revenue TTM 428.9m) / Revenue TTM)
Gross Margin QoQ = 19.35% (prev 17.51%)
Tobins Q-Ratio = 1.46 (Enterprise Value 863.2m / Total Assets 591.4m)
Interest Expense / Debt = 1.59% (Interest Expense 2.65m / Debt 167.1m)
Taxrate = 20.54% (3.75m / 18.3m)
NOPAT = 43.5m (EBIT 54.7m * (1 - 20.54%))
Current Ratio = 2.37 (Total Current Assets 226.9m / Total Current Liabilities 95.7m)
Debt / Equity = 0.62 (Debt 167.1m / totalStockholderEquity, last quarter 271.3m)
Debt / EBITDA = 1.94 (Net Debt 141.5m / EBITDA 73.1m)
Debt / FCF = 4.06 (Net Debt 141.5m / FCF TTM 34.9m)
Total Stockholder Equity = 259.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.43% (Net Income 32.1m / Total Assets 591.4m)
RoE = 12.38% (Net Income TTM 32.1m / Total Stockholder Equity 259.5m)
RoCE = 14.65% (EBIT 54.7m / Capital Employed (Equity 259.5m + L.T.Debt 114.1m))
RoIC = 11.39% (NOPAT 43.5m / Invested Capital 381.8m)
WACC = 9.75% (E(721.7m)/V(888.8m) * Re(11.71%) + D(167.1m)/V(888.8m) * Rd(1.59%) * (1-Tc(0.21)))
Discount Rate = 11.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.50%
[DCF Debug] Terminal Value 70.45% ; FCFE base≈38.5m ; Y1≈47.5m ; Y5≈81.1m
Fair Price DCF = 16.80 (DCF Value 782.1m / Shares Outstanding 46.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 44.47 | EPS CAGR: 2.57% | SUE: 1.90 | # QB: 1
Revenue Correlation: 66.86 | Revenue CAGR: 1.95% | SUE: 1.05 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=-0.020 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=0.75 | Chg30d=-0.083 | Revisions Net=-2 | Growth EPS=+1.6% | Growth Revenue=-0.8%
Additional Sources for CLB Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle